Theratechnologies Is Reinventing Itself

egrifta

It would be an understatement to say that specialty pharma companies have been popular among Canadian investors of late. A quick scan of the one-year charts on Cipher Pharmaceuticals (TSX:CPH), Concordia Healthcare (TSX:CXR), and BioSyent (TSXV:RX) is illustrative of how in vogue this sector has become. With the space squarely on Canadian investor’s radar, I […]

Ottawa’s Privacy Analytics Participates in HITRUST Health De-Identification Framework

Pharmacy

A U.S. coalition called HITRUST has created a De-Identification Framework for the healthcare industry, setting standards and controls for improving cybersecurity relating to patient health records. A Canadian company that specializes in data anonymization for the health industry, Ottawa’s Privacy Analytics, played a role in the framework’s development. De-Identification, in a nutshell, provides a way […]

Concordia Healthcare acquisition of Covis gets thumbs up at Laurentian

concordia healthcare

Laurentian Bank Securities analyst Joseph Walewicz likes Concordia Health Care’s (TSX:CXR) acquisition of Covis Pharma. This morning, Concordia announced it would buy Covis Pharma SARL and Covis Injectables SARL for (U.S.) $1.2-billion in cash. The company said it would finance the pickup through a combination of term loans, bonds and equity. “Covis’s strong commercial momentum […]

Oncolytics Biotech and Orphan Drug Designations: Wash, Rinse, Repeat

REOLYSIN

Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) yesterday announced it had received orphan drug designation from FDA for their oncology drug, REOLYSIN, in the treatment of primary peritoneal cancer. This is the fourth time in less than a month that the company has announced an FDA orphan drug designation for REOLYSIN. Prior to yesterday’s orphan drug designation announcement […]

BioSyent is poised for a great 2015, says Cantor Fitzgerald Canada

Biosyent's leading brand is FeraMAX. It currently markets two formulations for the treatment of iron deficient anemia.

Investors should take advantage of recent softness in shares of BioSyent (TSXV:RX), says Cantor Fitzgerald Canada analyst Scott Curtis. Yesterday, BioSyent reported its fourth quarter and fiscal 2014 results. For the year, the company earned $3.15-million on revenue of $12.21-million, a topline that was up 57% year-over-year. “Two thousand fourteen marked our fifth consecutive year […]

Prometic Life Sciences should have strong clinical news flow in 2015

Prometic Life Sciences CEO Pierre Laurin

This past Friday, the tape was telling investors that something was up at Prometic Life Sciences (TSX:PLI). Prometic stock was surging on above average volume, even though there was no news from the company. Ultimately, IIROC stepped in and halted the stock late in the day due to pending news. Yesterday, investors learned that the […]

Oncolytics Biotech rises after FDA grants Reolysin orphan status for pancreatic cancer

REOLYSIN

Shares of Oncolytics Biotech (TSX:ONC, Nasdaq:ONCY) are up today after the company announced that the FDA had granted orphan drug designation lead product candidate, Reolysin, which is designed to treat various cancers. Today’s status relates to the treatment of pancreatic cancer. “This is the second indication for which we have received orphan drug designation in […]

Could Legal “Made in Canada” Marijuana Become a Global Export?

canadian club boardwalk empire

For decades, illegal marijuana has made its way down to the United States from Canada. “B.C. Bud” is a brand name that resonates with recreational marijuana users from Seattle to Sarasota. But could Canada’s first mover advantage in the business of marijuana translate into an industry that we could ultimately export to the United States? […]

Merus Labs rises on improved first quarter results

Sintrom

Shares of Merus Labs (TSX:MSL) are up today after the company reported better than expected first quarter results. In its Q1, reported after market yesterday, Merus lost $216,044 on revenue of $10.6-million, a topline that was up 70% over last year’s first quarter. “I am pleased with the substantial progress that our expanded Merus team […]